2025年，对百时美施贵宝（BMS）中国而言，是承前启后的关键之年。 如果说四十多年前，这家最早进入中国市场的来自美国的跨国药企，"看好"的是中国巨大的市场潜力； 那么今天，其在中国的战略重心已经从"开拓市场"转向"共建生态"。 百时美施贵宝副总裁、新任中国总经理钱江指出，BMS对中国的"看好"始终不变，但"看好"的内核已经 发生更迭。"今天，我们看好中国市场，不再仅仅把它视作为一个'销售市场'，而是将其定位为一个我 们能够与之'共同创新的生态系统'。在这里，双向赋能是路径，双向创新是目标。" 作为一位深耕医药行业近三十年的实干型领导者，钱江于2025年7月就任这一职位。他的履新本身就是 BMS与中国创新生态"双向赋能"的例证 —— 他曾任联拓生物首席商业官兼中国总经理。在BMS从联拓 生物获得在中国和其他亚洲市场开发和商业化全球首创心肌肌球蛋白抑制剂独家权利的合作过程中，双 方不仅达成了交易，也实现了人才与创新的互联、互通和互赢。 从"看好市场"到"看好市场且看好创新"，BMS早在2020年就前瞻性地在中国提出了公司的"中国2030战 略"。在这一"十年长期战略"行至半程之际，钱江为BMS中国团队明确了三件 ...

百时美施贵宝副总裁、新任中国总经理钱江指出，BMS对中国 的"看好"始终不变，但"看好"的内核已经发生更迭。"今天， 我们看好中国市场，不再仅仅把它视作为一个'销售市场'，而 是将其定位为一个我们能够与之'共同创新的生态系统'。在这 里，双向赋能是路径，双向创新是目标。" 作者：张易 封图：图片资料室 2025年，对百时美施贵宝（BMS）中国而言，是承前启后的关键之年。 如果说四十多年前，这家最早进入中国市场的来自美国的跨国药企，"看好"的是中国巨大的市场 潜力；那么今天，其在中国的战略重心已经从"开拓市场"转向"共建生态"。 百时美施贵宝副总裁、新任中国总经理钱江指出，BMS对中国的"看好"始终不变，但"看好"的内 核已经发生更迭。" 今天，我们看好中国市场，不再仅仅把它视作为一个'销售市场'，而是将其定 位为一个我们能够与之'共同创新的生态系统'。在这里，双向赋能是路径，双向创新是目标。 " 作为一位深耕医药行业近三十年的实干型领导者，钱江于2025年7月就任这一职位。他的履新本 身就是BMS与中国创新生态"双向赋能"的例证 —— 他曾任联拓生物首席商业官兼中国总经理。 在BMS从联拓生物获得在中国和其他 ...

Core Insights - Bristol-Myers Squibb is focusing on advancements in hematology treatments, which are expected to significantly impact patient care and the company's future [2][3]. Company Overview - The conference call is led by Kate Bender from Investor Relations, highlighting the company's commitment to discussing key programs in hematology [2]. - Cristian Massacesi, the Chief Medical Officer, will present the company's slide presentation, followed by a Q&A session with other leaders in the organization [3]. Future Plans - The company will provide forward-looking statements regarding its future plans and prospects, acknowledging that actual results may vary due to various factors [4].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Bristol-Myers Squibb Company (NYSE:BMY) Update / Briefing December 11, 2025 09:00 AM ET Company ParticipantsLynelle Hoch - President of Cell Therapy OrganizationMalcolm Hoffman - Biopharma Senior Equity Research AssociateMonica Shaw - Senior Vice President of Oncology CommercializationChristian Massacesi - CMO and Head of Global Drug DevelopmentRosanna Ricafort - Vice President of Hematology and Cell Therapy Global Drug DevelopmentLuisa Hector - Head of Global Pharmaceutical Equity ResearchMatt Phipps - Gro ...

富国银行将施贵宝的目标价从53美元上调至55美元，维持"持有"评级。(格隆汇) ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase. ...

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is highlighted as a strong investment opportunity in the pharmaceutical sector, with Jefferies maintaining a Buy rating and a price target of $68 [1]. Group 1: Analyst Ratings - Scotiabank raised its price target for Bristol-Myers Squibb from $45 to $53 while keeping a Sector Perform rating, citing expectations for pivotal data readouts in 2026 that present an upside risk/reward [2]. - Leerink also maintained an Outperform rating as the company expands its ADEPT-2 enrollment [2]. Group 2: FDA Approval and Product Details - The FDA approved Breyanzi for treating adult patients with relapsed or refractory marginal zone lymphoma who have undergone at least two prior systemic therapies, marking it as the only FDA-approved CAR T cell therapy for five cancer types [3][4]. - Breyanzi demonstrated a durable response in 95.5% of patients in the MZL cohort of the TRANSCEND FL study, alongside a consistent safety profile [4]. Group 3: Company Overview - Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering advanced medicines for serious diseases across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience [5].

Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential. ...

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs are an exciting development, for sure. However, Wall Street has a bad habit of getting so myopically focused on one thing that stock prices become irrational.This is why you might want to look at Bristol ...